PMID- 29311456
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20180226
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 138
IP  - 1
DP  - 2018
TI  - [A Survey of the Adverse Effects and Influence of Concomitant Drugs for 
      Methotrexate Intrathecal Administration].
PG  - 111-115
LID - 10.1248/yakushi.17-00122 [doi]
AB  -  In general, the intraventricular administration of cytotoxic antitumor drugs 
      provides a high drug concentration in the cerebrospinal fluid with a reduced risk 
      of systemic adverse reactions. Methotrexate (MTX) high-dose therapy requires 
      close monitoring when performed in combination with trimethoprim-sulfamethoxazole 
      (ST) therapy and proton pump inhibitor (PPI) and nonsteroidal anti-inflammatory 
      drug administration for excretion delay and toxicity enhancement. While the 
      frequency of systemic side effects is thought to be low with intrathecal 
      administration, such effects do rarely but occasionally occur. We must consider 
      drug interactions with combination therapy as a potential factor inducing such 
      effects. We examined the patients who received MTX intrathecal administration at 
      Fukuoka University Hospital from January 2013 to December 2014 with respect to 
      the onset of side effects and combination therapy. MTX intrathecal administration 
      was performed a total of 79 times in 27 patients. In five of these 27 patients, 
      MTX intrathecal administration was performed twice a week, and hematotoxicity and 
      non-hematotoxicity developed in two patients in whom ST was also administered. On 
      the other hand, even if ST and/or PPI was administered, no side effects were 
      observed in the patients administered levofolinate.
FAU - Uchiyama, Masanobu
AU  - Uchiyama M
AD  - Department of Pharmacy, Fukuoka University Hospital.
FAU - Ueno, Miho
AU  - Ueno M
AD  - Department of Pharmacy, Fukuoka University Hospital.
FAU - Takamatsu, Yasushi
AU  - Takamatsu Y
AD  - Division of Medical Oncology, Hematology and Infection Diseases, Department of 
      Medicine, Fukuoka University.
FAU - Matsuo, Koichi
AU  - Matsuo K
AD  - Department of Pharmacy, Fukuoka University Chikushi Hospital.
FAU - Imakyure, Osamu
AU  - Imakyure O
AD  - Department of Pharmacy, Fukuoka University Chikushi Hospital.
FAU - Kamimura, Hidetoshi
AU  - Kamimura H
AD  - Department of Pharmacy, Fukuoka University Hospital.
LA  - jpn
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Proton Pump Inhibitors)
RN  - 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*administration & dosage/*adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Antimetabolites, Antineoplastic/*administration & dosage/*adverse effects
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Injections, Spinal
MH  - Male
MH  - Methotrexate/*administration & dosage/*adverse effects
MH  - Middle Aged
MH  - Proton Pump Inhibitors/administration & dosage/adverse effects
MH  - Trimethoprim, Sulfamethoxazole Drug Combination/*administration & dosage/*adverse 
      effects
OTO - NOTNLM
OT  - adverse event
OT  - concomitant drug
OT  - intrathecal administration
OT  - methotrexate
EDAT- 2018/01/10 06:00
MHDA- 2018/02/27 06:00
CRDT- 2018/01/10 06:00
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
AID - 10.1248/yakushi.17-00122 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2018;138(1):111-115. doi: 10.1248/yakushi.17-00122.